[SUNWAY] QoQ TTM Result on 31-Mar-2023 [#1]

Stock
[SUNWAY] SUNWAY BERHAD
Announcement Date
24-May-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
31-Mar-2023 [#1]
Profit Trend
QoQ- 0.23%
YoY- -75.31%
Quarter Report
Latest QR
Upcoming QR
SUNWAY's Result
SUNWAY's Financial Summary
View:
Show?
TTM Result
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Revenue 6,139,797 5,802,638 5,534,026 5,346,213 5,194,951 4,907,190 4,701,684 19.41%
PBT 993,243 936,749 912,724 924,734 919,791 882,532 772,602 18.17%
Tax -137,685 -178,276 -179,327 -172,322 -166,951 2,153,485 2,176,387 -
NP 855,558 758,473 733,397 752,412 752,840 3,036,017 2,948,989 -56.07%
-
NP to SH 737,775 674,853 659,275 678,218 676,691 2,929,085 2,845,461 -59.23%
-
Tax Rate 13.86% 19.03% 19.65% 18.63% 18.15% -244.01% -281.70% -
Total Cost 5,284,239 5,044,165 4,800,629 4,593,801 4,442,111 1,871,173 1,752,695 108.27%
-
Net Worth 13,025,455 12,992,011 12,697,388 12,672,407 12,555,068 12,437,729 12,320,392 3.76%
Dividend
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Div 330,157 323,455 323,455 322,676 322,676 205,339 205,339 37.12%
Div Payout % 44.75% 47.93% 49.06% 47.58% 47.68% 7.01% 7.22% -
Equity
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Net Worth 13,025,455 12,992,011 12,697,388 12,672,407 12,555,068 12,437,729 12,320,392 3.76%
NOSH 5,500,667 4,999,675 4,999,644 4,934,081 4,934,079 4,934,079 4,934,079 7.49%
Ratio Analysis
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
NP Margin 13.93% 13.07% 13.25% 14.07% 14.49% 61.87% 62.72% -
ROE 5.66% 5.19% 5.19% 5.35% 5.39% 23.55% 23.10% -
Per Share
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
RPS 101.34 97.81 93.71 91.13 88.55 83.64 80.14 16.88%
EPS 12.18 11.38 11.16 11.56 11.53 49.93 48.50 -60.09%
DPS 5.45 5.50 5.50 5.50 5.50 3.50 3.50 34.23%
NAPS 2.15 2.19 2.15 2.16 2.14 2.12 2.10 1.57%
Adjusted Per Share Value based on latest NOSH - 4,934,081
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
RPS 107.08 101.20 96.51 93.24 90.60 85.58 82.00 19.41%
EPS 12.87 11.77 11.50 11.83 11.80 51.08 49.62 -59.22%
DPS 5.76 5.64 5.64 5.63 5.63 3.58 3.58 37.18%
NAPS 2.2716 2.2658 2.2144 2.21 2.1896 2.1691 2.1486 3.77%
Price Multiplier on Financial Quarter End Date
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Date 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 -
Price 2.06 1.97 1.58 1.59 1.62 1.57 1.70 -
P/RPS 2.03 2.01 1.69 1.74 1.83 1.88 2.12 -2.84%
P/EPS 16.92 17.32 14.15 13.75 14.05 3.14 3.51 184.54%
EY 5.91 5.77 7.07 7.27 7.12 31.80 28.53 -64.88%
DY 2.65 2.79 3.48 3.46 3.40 2.23 2.06 18.22%
P/NAPS 0.96 0.90 0.73 0.74 0.76 0.74 0.81 11.95%
Price Multiplier on Announcement Date
31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 CAGR
Date 21/02/24 22/11/23 24/08/23 24/05/23 23/02/23 25/11/22 24/08/22 -
Price 2.71 1.94 1.91 1.55 1.62 1.58 1.66 -
P/RPS 2.67 1.98 2.04 1.70 1.83 1.89 2.07 18.43%
P/EPS 22.25 17.05 17.11 13.41 14.05 3.16 3.42 247.31%
EY 4.49 5.86 5.84 7.46 7.12 31.60 29.22 -71.21%
DY 2.01 2.84 2.88 3.55 3.40 2.22 2.11 -3.17%
P/NAPS 1.26 0.89 0.89 0.72 0.76 0.75 0.79 36.39%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment